Abstracts tagged "Bone marrow and scleroderma"

Abstract Number: 1502 • 2012 ACR/ARHP Annual Meeting
Hedgehog Signaling in Murine Chronic Sclerodermatous Graft-Versus-Host Disease
Pawel Zerr¹, Katrin Palumbo-Zerr¹, Alfiya Distler², Michal Tomcik³, Stefan Vollath², Louis E. Munoz², Christian Beyer⁴, Clara Dees⁵, Friederike Egberts⁶, Ilaria Tinazzi⁷, Francesco Del Galdo⁸, Oliver Distler⁹, Georg Schett¹⁰, Bernd M. Spriewald¹¹ and Joerg HW Distler², ¹Department of Internal Medicine 3 and Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague 2, Czech Republic, ⁴Department of Internal Medicine 3, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Department of Dermatology, Department of Dermatology, Schleswig-Holstein University Hospital, Campus Kiel, Kiel, Germany, ⁷Unit of Rheumatology, Scleroderma Research Program, Leeds Institute of Molecular Medicine, Division of Musculoskeletal Diseases, University of Leeds, Leeds, United Kingdom, ⁸Musculoskeletal Diseases, Scleroderma Research Program, Leeds Institute of Molecular Medicine, Division of Musculoskeletal Diseases, University of Leeds, Leeds, United Kingdom, ⁹Department of Rheumatology, Center of Experimental Rheumatology and Zurich Center of Integrative Human Physiology, University Hospital Zurich, Zurich, Switzerland, ¹⁰Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ¹¹Department of Internal Medicine V, Department of Internal Medicine V, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Sclerodermatous chronic graft-versus-host disease (cGvHD) is a prognosis limiting complication of allogeneic bone marrow transplantation. cGvHD can manifest on virtually every organ system. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].